Poussot to take over as Wyeth CEO

Share this article:

Wyeth will promote its No. 2 executive, Bernard Poussot, to CEO effective Jan.1 under a planned succession, the drugmaker said.

Poussot will succeed current CEO Robert Essner, who will become non-executive chairman of the board during a transition period beginning in the new year.

Poussot has served as Wyeth's president and vice chairman since April 2006. In January he added the role of chief operating officer.

Essner has worked at Wyeth since 1989 and has been CEO since May 2001.
 

Share this article:
close

Next Article in News

Email Newsletters

More in News

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...

FDA kind of OKs Lilly/BI's Lantus look-alike

FDA kind of OKs Lilly/BI's Lantus look-alike

Sanofi's patent lawsuit triggered the tentative approval of the Lilly-BI Lantus competitor.

GSK relaunches COPD.com

GSK relaunches COPD.com

The refresh launched soon after the company encouraged investors to take a long view of GSK as the firm posted weak respiratory numbers.